- Home
- GALT vs NHS Comparison
GALT vs NHS Comparison
Compare GALT & NHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | NHS |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 199.2M | 199.8M |
| IPO Year | 2008 | N/A |
Fundamental Metrics
Financial Performance| Metric | GALT | NHS |
|---|---|---|
| Price | $2.38 | $6.30 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 303.0K | 201.9K |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.44% |
| EPS Growth | ★ 36.84 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.32 | $6.13 |
| 52 Week High | $7.13 | $7.75 |
Technical Indicators
Market Signals| Indicator | GALT | NHS |
|---|---|---|
| Relative Strength Index (RSI) | 48.36 | 40.31 |
| Support Level | $2.09 | $6.27 |
| Resistance Level | $2.60 | $6.54 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 22.92 | 37.50 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About NHS Neuberger Berman High Yield Strategies Fund
Neuberger Berman High Yield Strategies Fund Inc is a diversified, closed-end management investment company. The company invests in high yield debt securities market. The Fund uses leverage to pursue its investment objective. The Fund may invest in a variety of direct debt instruments, including bank loans, notes and other interests in amounts owed to financial institutions by borrowers, such as companies and governments. Corporate loans in which the Fund may invest will consist of direct obligations of borrowers. The Fund may invest in corporate loans at origination as a co-lender or may acquire loans in the secondary market by purchasing participations in, assignments of or novations of corporate loans.